SEC Comment Letter for Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502) (QNRX) — Dec 17, 2024
Quoin Pharmaceuticals, Ltd. (QNRX) (CIK 0001671502)
Date: Dec. 17, 2024 · CIK: 0001671502 · Accession: 0000000000-24-013864
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283734
Letter
December 17, 2024 Michael Myers Chief Executive Officer Quoin Pharmaceuticals Ltd. 42127 Pleasant Forest Court Ashburn, VA 20148 Re:Quoin Pharmaceuticals Ltd. Registration Statement on Form S-1 Filed December 11, 2024 File No. 333-283734 Dear Michael Myers: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Melissa Palat Murawsky, Esq.
Show Raw Text
December 17, 2024
Michael Myers
Chief Executive Officer
Quoin Pharmaceuticals Ltd.
42127 Pleasant Forest Court
Ashburn, VA 20148
Re:Quoin Pharmaceuticals Ltd.
Registration Statement on Form S-1
Filed December 11, 2024
File No. 333-283734
Dear Michael Myers:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Melissa Palat Murawsky, Esq.